ClinicalTrials.gg
Active, not recruitingNCT05434312Updated Feb 24, 2025

TGRX-678 Chinese Phase I in Chronic Myelogenous Leukemia (CML) Patients

A Phase 1 interventional study of TGRX-678 in Chronic Myelogenous Leukemia, sponsored by Shenzhen TargetRx, Inc.. Active, not recruiting at 1 site in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2025-02-24.

Sponsored by Shenzhen TargetRx, Inc. · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Primary completion was expected by Mar 2026, 8 months ago, but the record still lists the study as active, not recruiting.
  • Registered 1 year 1 month after the study started (first participant enrolled Mar 2021, registered May 2022).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
90
Allocation
Not applicable
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 49 studies in Leukemia, Myelogenous, Chronic, BCR-ABL Positive with a site in China — 11 open to participants now, 14 under way, 2 of them phase 3. Leukemia, Myelogenous, Chronic, BCR-ABL Positive · China.

Planned enrollment
23rd of 37
90 · median 144
Started
2021
with 6 others
Phase 1
9 of 49
1 open now
Primary completion
2026-03
later than 1 of 13 live
Registered
37th of 49
by date
Lead sponsor
3 of 49
Shenzhen TargetRx, Inc.

Among the 49 studies in Leukemia, Myelogenous, Chronic, BCR-ABL Positive with a site in China, this one is the 23rd largest by planned enrollment of the 37 interventional ones that give a count, is one of 7 that started in 2021, is one of 9 in phase 1, reaches primary completion later than 1 of the 13 other live ones, and was the 37th registered.

Leukemia, Myelogenous, Chronic, BCR-ABL Positive

894 studies on the registry are indexed under Leukemia, Myelogenous, Chronic, BCR-ABL Positive; 109 are open to participants now.

Browse Leukemia, Myelogenous, Chronic, BCR-ABL Positive studies →

Open to participants now

11 of the 49 studies in Leukemia, Myelogenous, Chronic, BCR-ABL Positive with a site in China are open now. Recruiting first, the newest first:

6 more — sign in →

All 11 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 79 Leukemia, Myelogenous, Chronic, BCR-ABL Positive studies recruiting now, 48 (61%) set no upper age limit and 20 (25%) stop at 75 or younger; 20 take children under 18; 7 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 49 studies in Leukemia, Myelogenous, Chronic, BCR-ABL Positive with a site in China, or all of them as a file.
02

Study summary

The purpose of this single- arm, open-lable, dose escalation + dose expansion study is to evalulate the safety, tolerability, pharmacokinetic and preliminary efficacy of TGRX-678 in Chronic Myelogenous Leukemia patients who had failure with or are intolerant to TKI treatments.

Read the detailed description

This is the first-in-human trial with TGRX-678 which aims to evaluate the safety profile and preliminary efficacy profile in advanced or refractory CML patients with previous failure or intolerence to TKI treatments. The primary purpose of this study is to evaluate the safety profile of TGRX-678, including determination of the maximal tolerated dose (MTD) and recommended phase II dose (RP2D), and other safety measures of the investigational drug, such as adverse events and abnormal clinical outcomes. Preliminary efficacy profile of TGRX-678 is evaluated based on the changes in peripheral blood cells and disease-associated cytogenetic markers. The safety, tolerability and efficacy profiles, along with pharmacokinetic analysis, will be assessed together to determine the optimal dose for expansion.

03

Conditions studied

  • Chronic Myelogenous Leukemia
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Willing to participate in the study with ;
  • 18-75 years of age at the time of screening;
  • Male or female;
  • Diagnosis of CML-CP by cytomorphological examination of the bone marrow, molecular biology examination, or cytogenetic testing during the screening period (according to the NCCN guidelines (NCCN, 2021);
  • Received prior treatment with imatinib, dasatinib or nilotinib; patients must be intolerant or resistant to the above drugs according to MD Anderson or ELN guidelines;
  • performance status ≤ 2;
  • Minimum of 3 months;
  • Adequate renal function, defined as serum creatinine \<1.5× upper limit of normality ()
  • Adequate liver function, defined as total \<1.5× ULN, and ALT \<2.5×ULN; if liver function is compromised due to CML, AST and ALT \<5×ULN;
  • Adequate coagulation function, defined as PT\<1.5×ULN, \<1.5×ULN, and APTT\<1.5×ULN;
  • Normal pancreatic function, defined as lipase and amylase \<1.5× ULN;
  • Normal , defined as ≤450 ms in males and ≤470 ms in females, as indicated by screening results;
  • For women with , negative pregnancy test result at screening period;
  • Pregnant or breast feeding and female patients of childbearing potential must agree to use effective methods of .

Exclusion criteria

Exclusion Criteria:

  • Received TKI treatment within 7 days of first dosing of the drug, or AEs related to previous treatment has not been recovered to Grade 1 or lower (except for alopecia);
  • Exposure to other antineoplastic therapies and either of the following: hydroxyurea or anagrelide within 24 h prior to the first dose; interferon or immunotherapy within 14 days prior to the first dose, or any other cytotoxic chemotherapy, radiotherapy, or investigational therapy (excluding any TKI therapy) within 28 days prior to the first dose;
  • Stem cell transplant \< 60 days prior to the first dose, with evidence of (GVHD) or GVHD requiring therapy;
  • Concomitant immunosuppressive therapy (other than short term treatment);
  • Exposure to drugs related to torsade de pointes within 1 month of the screening period;
  • Cytological or pathological diagnosis of active central nervous system disorder;
  • CML-CP patients already achieved complete cytogenetic response;
  • CML-AP patients already achieved major hematological response;
  • Significant uncontrolled cardiac disease;
  • Uncontrolled hypertension (Diastolic BP > 85mm Hg; Systolic > 145 mm Hg; achieved with or without medication);
  • Exposure to herbal preparations or over-the-counter medications containing herbal ingredients within 2 weeks prior to the first dose;
  • Severe hemorrhagic disorders unrelated to CML;
  • History of grade 3-4 pancreatitis or history of alcohol abuse;
  • Uncontrolled hyper-triglyceridemia (TG>450 mg/dL);
  • Malabsorption syndrome or other illness that could affect oral absorption;
  • Diagnosis of another primary in the past 3 years (other than non-melanoma skin cancer, cervical carcinoma in situ, or controlled prostate cancer that have been cured within 3 years;
  • Invasive/extensive surgery within 14 days prior to initiating TGRX-678 therapy;
  • Active infections, including syphilis, , or ;
  • Other criteria in the opinion of the investigator or the medical monitor that is unsuitable for the study, including diseases that could compromise the patients safety or the evaluation of the drugs safety or poor compliance.
Terms in these criteria, in plain language(20)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

GVHD (graft-versus-host disease)

After a transplant from a donor, the donor’s immune cells attack the recipient’s body, often the skin, gut or liver.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
90 participants (estimated)

Study arms

  • Experimental
    TGRX-678

    Subjects to be treated with the investigational drug TGRX-678

    Drug: TGRX-678

Interventions

  • Participants are given TGRX-678 tablets orally at one of the dose levels as pre-determined for the dose escalation sequence.

06

What researchers measure

Primary outcomes

  1. Maximal tolerated dose (MTD)

    To determine the MTD of TGRX-678 in CML patients

    Time frame: At end of Cycle 1 (each cycle is 28 days) when the posterior probability of DLT of a dose level is higher than 33%

  2. Recommended phase II dose (RP2D)

    To detemine the RP2D of TGRX-678 in CML patients for Phase II

    Time frame: At completion of the study, an average of 1.5 years

  3. Safety profile (DLT)

    to record and analyse subjects with dose-limiting toxicities (DLTs)

    Time frame: DLT: collect during Cycle 1 (28 days)

  4. Safety profile (AEs/SAEs)

    to record and analyse subjects with adverse events (AEs) and serious adverse events (SAEs), and

    Time frame: AE and SAE: through completion of the study, an average of 1.5 years

Secondary outcomes

  1. Hematologic Response

    To record and analyse the hematologic response of subjects. Subjects will be determined whether complete hematologic response (CHR) or no evience of leukemia (NEL) is reached.

    Time frame: at screening period, weekly in Cycle 1, bi-weekly in Cycle 2 and monthly starting from Cycle 3 (each cycle is 28 days)

  2. Cytogenetic Response

    To record and analyse the cytogenetic response of subjects subjects will be determined whether partial or complete cytogenetic response (Ph+ \< 35%) is reached.

    Time frame: at screening period, weekly in Cycle 1, bi-weekly in Cycle 2 and monthly starting from Cycle 3 (each cycle is 28 days)

  3. Molecular Response

    To record and analyse the molecular response of subjects Subjects will be detmined whether major molecular response (BCR-ABL1 (IS) no more than 0.1%) is reached.

    Time frame: at screening period, weekly in Cycle 1, bi-weekly in Cycle 2 and monthly starting from Cycle 3 (each cycle is 28 days)

  4. Plasma Cmax

    Cmax of TGRX-678 as measured in plasma

    Time frame: Day 1, 7, 21, 28 of Cycle 1, Cycle 2 Day 28 and Cycle 3 Day 28

  5. Plasma Tmax

    Tmax of TGRX-678 as measured in plasma

    Time frame: Day 1, 7, 21, 28 of Cycle 1, Cycle 2 Day 28 and Cycle 3 Day 28

  6. Plasma T1/2

    Half life of TGRX-678 as measured in plasma

    Time frame: Day 1, 7, 21, 28 of Cycle 1, Cycle 2 Day 28 and Cycle 3 Day 28

  7. Plasma AUClast

    AUClast of TGRX-678 as measured in plasma

    Time frame: Day 1, 7, 21, 28 of Cycle 1, Cycle 2 Day 28 and Cycle 3 Day 28

  8. Plasma AUCinf

    AUCinf of TGRX-678 as measured in plasma

    Time frame: Day 1, 7, 21, 28 of Cycle 1, Cycle 2 Day 28 and Cycle 3 Day 28

  9. Plasma Cmin

    Cmin of TGRX-678 as measured in plasma

    Time frame: Day 1, 7, 21, 28 of Cycle 1, Cycle 2 Day 28 and Cycle 3 Day 28

  10. Plasma AUCss

    steady state AUC of TGRX-678 as measured in plasma

    Time frame: Day 1, 7, 21, 28 of Cycle 1, Cycle 2 Day 28 and Cycle 3 Day 28

  11. Plasma Cmax,ss

    steady state Cmax of TGRX-678 as measured in plasma

    Time frame: Day 1, 7, 21, 28 of Cycle 1, Cycle 2 Day 28 and Cycle 3 Day 28

  12. Plasma Tmax,ss

    steady state Tmax of TGRX-678 as measured in plasma

    Time frame: Day 1, 7, 21, 28 of Cycle 1, Cycle 2 Day 28 and Cycle 3 Day 28

  13. CL

    Clearance of TGRX-678 as measured in plasma

    Time frame: Day 1, 7, 21, 28 of Cycle 1, Cycle 2 Day 28 and Cycle 3 Day 28

  14. Vd

    Volume of distribution of TGRX-678 as measured in plasma

    Time frame: Day 1, 7, 21, 28 of Cycle 1, Cycle 2 Day 28 and Cycle 3 Day 28

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Mar 2021 (actual). Primary completion is estimated for Mar 2026, 60 months after the start.

Of 56 phase 1 interventional studies under Leukemia, Myelogenous, Chronic, BCR-ABL Positive, half reached primary completion within 58 months of starting (the median), counting those still running; a quarter within 41 and three quarters within 95. This study's planned 60 months is close to that.

How these figures are worked out, and which studies are left out of them.

Registered
May 23, 2022
First posted
Jun 28, 2022
StartActual
Mar 29, 2021
Primary completionEst.
Mar 2026
CompletionEst.
Sep 2026
Last update
Feb 24, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 24, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05434312
Lead sponsor
Shenzhen TargetRx, Inc.
Responsible party
Sponsor
First posted
Jun 28, 2022
Start date
Mar 29, 2021
Primary completion
Mar 2026 (estimated)
Completion
Sep 2026 (estimated)
Last update
Feb 24, 2025

Study contacts

Qian Jiang, MD
principal investigator · Peking University People's Hospital

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Feb 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Meribatinib

Start the discussion